Goodwin Procter advised STALICLA on the deal.STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental disorders…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
